Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?
暂无分享,去创建一个
[1] C. Chao,et al. Tedizolid Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection: A Systematic Review and Meta-Analysis , 2019, Antibiotics.
[2] H. Wertheim,et al. Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models. , 2019, The Journal of antimicrobial chemotherapy.
[3] H. Wertheim,et al. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria , 2019, The Journal of antimicrobial chemotherapy.
[4] R. Hall,et al. An evaluation of tedizolid for the treatment of MRSA infections , 2018, Expert opinion on pharmacotherapy.
[5] H. Wertheim,et al. Minocycline Has No Clear Role in the Treatment of Mycobacterium abscessus Disease , 2018, Antimicrobial Agents and Chemotherapy.
[6] J. Mainardi,et al. In Vitro and Intracellular Activity of Imipenem Combined with Tedizolid, Rifabutin, and Avibactam against Mycobacterium abscessus , 2018, Antimicrobial Agents and Chemotherapy.
[7] J. Gaillard,et al. In vitro activity of tedizolid against the Mycobacterium abscessus complex. , 2017, Diagnostic microbiology and infectious disease.
[8] D. Deshpande,et al. A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease , 2017, The Journal of antimicrobial chemotherapy.
[9] D. Deshpande,et al. Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease , 2017, The Journal of antimicrobial chemotherapy.
[10] R. Wallace,,et al. In Vitro Susceptibility Testing of Tedizolid against Nontuberculous Mycobacteria , 2017, Journal of Clinical Microbiology.
[11] J. Yuste,et al. Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity , 2017, The Journal of antimicrobial chemotherapy.
[12] J. Stout,et al. Update on pulmonary disease due to non-tuberculous mycobacteria. , 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[13] R. Gibson,et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary , 2015, Thorax.
[14] S. Burdette,et al. Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] S. Wicha,et al. Pharmacodynamic and response surface analysis of linezolid or vancomycin combined with meropenem against Staphylococcus aureus , 2015, Pharmaceutical Research.
[16] C. Daley,et al. The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease , 2015, European Respiratory Journal.
[17] D. van Soolingen,et al. Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence , 2013, Expert review of anti-infective therapy.
[18] F. Drobniewski,et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study , 2013, European Respiratory Journal.
[19] J. Philley,et al. Management of Nontuberculous Mycobacterial (NTM) Lung Disease , 2013, Seminars in Respiratory and Critical Care Medicine.
[20] D. Nicolau,et al. Pulmonary Disposition of Tedizolid following Administration of Once-Daily Oral 200-Milligram Tedizolid Phosphate in Healthy Adult Volunteers , 2012, Antimicrobial Agents and Chemotherapy.
[21] Robert Horsburgh,et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.
[22] F. Odds,et al. Synergy, antagonism, and what the chequerboard puts between them. , 2003, The Journal of antimicrobial chemotherapy.
[23] J. Golden,et al. Intrapulmonary Pharmacokinetics of Linezolid , 2002, Antimicrobial Agents and Chemotherapy.